Auch wir verwenden Cookies. Mehr Informationen in der Datenschutzerklärung

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

TheMotleyFool

0 0

This Pharma Stock Is Poised to Keep Outperforming the S&P 500: https://g.foolcdn.com/editorial/images/778932/pharma-researcher.jpg

AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of achieving annual revenue exceeding $45 billion by 2023.

This target was met with skepticism by Wall Street and dismissed as excessively optimistic. Contrary to these doubts, however, AstraZeneca realized this revenue milestone and surpassed the S&P 500 in total returns, including dividends, within the same time frame.